Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 2 studies described adult participants.

1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.

1 study contains conflicting p-value and significance fields; those significance claims are suppressed.

Placebo Group

Core clinician-reference fields are available or not applicable.

Participants received curcumin capsules twice daily for 12 months.

Curcumin Group

Participants consumed three blinded capsules of either curcumin (250 mg of curcuminoids per capsule) or placebo twice daily, for a total of six capsules per day over 12 months.

Participants received placebo capsules twice daily for 12 months.

Curcumin improves glycemic control and reduces inflammation in T2DM patients

Participants received 1500 mg of curcumin daily for 12 months.

In this 12-month, randomized, double-blind, placebo-controlled trial, 227 obese individuals with T2DM were assigned to receive either 1500 mg of curcumin daily or placebo.

Participants received placebo capsules for 12 months.

Participants ingested three blinded capsules of either curcumin (250 mg of curcuminoids per capsule) or placebo twice daily (six capsules per day) for 12 months.

Curcumin improves liver health in obese diabetes patients

Participants received 1500 mg/day curcumin supplementation for 12 months.

This randomized, double-blind, placebo-controlled trial evaluated the effects of 1500 mg/day curcumin supplementation for 12 months in 114 adults with T2DM.

Participants received a placebo treatment for 12 months.

Curcumin supplementation was associated with significant reductions compared with placebo.

Authoritative quality diagnostic: p value significance conflict.

Curcumin may improve inflammation and glycemic control in diabetes

3 of 3 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 5 of 5 supporting studies. 4 studies described participants with type 2 diabetes. 4 studies described adult participants.

2 relevant studies have unresolved authoritative design evidence and do not contribute to design-specific or RoB-specific claims.

Upstream consistency scoring indicates mixed findings across the evidence.

2 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, baseline_within_group, unknown_unresolved, usual_care.

2 supporting studies have high, serious, critical, unclear, or unavailable risk-of-bias information.

Structured population data were available for 3 of 3 supporting studies. 2 studies described participants with type 2 diabetes. 1 study described adult participants.

1 supporting study does not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: placebo, usual_care.

2 of 3 studies with duration data have follow-up of 12 weeks or less.

Structured population data were available for 4 of 4 supporting studies. 2 studies described participants with type 2 diabetes. 2 studies described adult participants.

3 of 4 studies with duration data have follow-up of 12 weeks or less.

Curcumin supplementation × Malondialdehyde (MDA)

Available supporting studies

Curcumin improves glycemic control and reduces inflammation in T2DM patients

Curcumin improves liver health in obese diabetes patients

Curcumin may improve inflammation and glycemic control in diabetes